0GQU Stock Chart & Stats
kr0.04
kr0.01(10.43%)
At close: 4:00 PM EST
kr0.04
kr0.01(10.43%)
Day’s Range― - ―
52-Week Rangekr3.81 - kr16.54
Previous CloseN/A
Volume200.00K
Average Volume (3M)196.00
Market Cap
kr127.45M
Enterprise Valuekr106.98
Total Cash (Recent Filing)kr43.90M
Total Debt (Recent Filing)kr100.00K
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding26,360,670
10 Day Avg. Volume35
30 Day Avg. Volume196
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)111.47
Price to Sales (P/S)0.00
P/FCF Ratio-191.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr21.50M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageThe sharp reduction in debt and near-zero debt-to-equity ratio reduce financing pressure and improve balance-sheet resilience. This gives Active Biotech greater flexibility to direct available resources toward clinical development while limiting exposure to interest and refinancing burdens.
Narrowing LossesThe narrowing net loss indicates some improvement in the company’s cost base or operating trajectory, even though profitability remains distant. If sustained, this trend could extend the runway of existing resources and reduce the pace at which future financing may be required.
Improving Cash-burn TrendOperating cash outflow has improved substantially over the reported periods, showing progress in controlling cash consumption. Continued improvement would strengthen the company’s ability to fund its development pipeline internally for longer, although cash generation has not yet been achieved.
Bears Say
No Operating RevenueZero reported revenue leaves the business without demonstrated operating monetization and makes its financial profile dependent on advancing and monetizing drug candidates. Until revenue emerges, scalability and the durability of the company’s funding model remain unproven.
Persistent Cash ConsumptionThe company continues to consume cash rather than generate it, creating an ongoing need to fund research and development through available resources or future financing. Persistent negative cash flow can constrain pipeline investment and weaken financial flexibility if progress remains slow.
Shrinking Equity BaseThe decline in equity alongside persistently negative returns indicates that losses are eroding the capital base. If this pattern continues, Active Biotech may face greater financing dependence and potential value dilution while it works to advance its clinical programs.
Active Biotech AB News
0GQU FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest share price was kr3.81 and its highest was kr16.54 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is kr127.45M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is Nov 05, 2026 which is in 56 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on Aug 20, 2026. The company reported -kr0.383 earnings per share for the quarter.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 26,360,670 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of -kr0.383 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in GB:0GQU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Oncopeptides AB
―
SynAct Pharma AB
―
Cantargia AB
―